| Company Name: | MannKind Corporation | | Ticker Symbol: | MNKD | | | WWW Address: | www.mannkindcorp.com | | CEO: | Alfred E. Mann | | No. of Employees: | 580 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 7.0 |  0.12 | 6.87 | 6.91 | 6.9 | 7.24 | 6.81 | 993703 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 789.6 | 112.8 | 1.12 | -2.98 | 0.00 | 0.0 | 0.0 | 12.30 - 2.00 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 6.88 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 776.1 | mil |
| Latest Shares Outstanding | 112.8 | mil |
| Earnings pS (EPS) | -2.98 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 34 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 56.0 | mil |
| Float as % of Shares Outstanding | 53.9 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -84.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -93.7 | % |
| Current Ratio | 2.2 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 101.0 | % |
| Working Capital pS | 0.31 | $ |
| Cash pS | 0.48 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.02 | $ |
| Cash Flow pS | -1.99 | $ |
| Free Cash Flow pS | -2.16 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -322.71 | |
| Price/Cash Flow | -3.5 | |
| Price/Free Cash Flow | -3.2 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 9.6 | 110 | 15,769 | 67,473 |
| 4 Weeks | 7.39 | 5.15 | 5.44 | 26.5 | 125 | 15,327 | 306,533 |
| 13 Weeks | 12.30 | 5.02 | 7.59 | -9.4 | 85 | 19,037 | 1,218,393 |
| 26 Weeks | 12.30 | 5.02 | 6.26 | 9.9 | 89 | 13,640 | 1,732,260 |
| 52 Weeks | 12.30 | 2.00 | 3.48 | 97.7 | 145 | 8,712 | 2,186,749 |
| YTD | 12.30 | 2.00 | - | 100.6 | 166 | 9,294 | 2,091,187 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 6.92 | 6.68 | 7.28 | 7.29 | 6.22 | 1.12 | 1.12 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 83.85 | NA | 82.83 |
| R&D | 32.64 | NA | 8.17 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -100.0 | 0.0 | 100.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.63 | 0.25 | 0.68 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 0.18 |
| Current Ratio | 1.0 |
| Quick Ratio (Acid Test) | 0.9 |
| Liquidity Ratio (Cash) | 0.87 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 0.6 |
| Working Capital pS | 0.00 |
| Cash-Flow pS | -2.85 |
| Free Cash-Flow pS | -3.47 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.63 |
| Financial Leverage Ratio (Assets/Equity) | 3.3 |
| Debt Ratio | 69.3 |
| Total Debt/Equity (Gearing Ratio) | 1.64 |
| LT Debt/Equity | 1.64 |
| LT Debt/Capital Invested | 62.1 |
| LT Debt/Total Liabilities | 72.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 1.02 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 9.93 |
| Tobin's Q Ratio | 2.75 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.15 |
| Enterprise Value (EV)/Free Cash Flow | -2.06 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -322.71 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -3.5 |
| Price/Free Cash Flow Ratio - LTM | -3.2 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 1.39 |
| Current Liabilities pS | 0.52 |
| Tangible Book Value pS - LTM | -0.02 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 2.03 |
| Cash pS - LTM | 0.48 |
| Cash Flow pS - LTM | -1.99 |
| Free Cash Flow pS - LTM | -2.16 |
| Earnings pS (EPS) | -2.98 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -1,768,705.00 |
| Free Cash Flow Margin 5YEAR AVG | -1,000,557.00 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -132.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -65.3 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -107.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | -57.9 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -0.0 |
| Effective Tax Rate - 5YEAR AVRG. | -0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 27,000 |
| Revenue per Employee | 34 |
| Net Income per Employee | -522,481 |
| Average Collection Period | 27,000 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 78,150.00 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.04 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 276715.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 628416.7 |
| Research & Devlopment (R&D) as % of Revenue | 1252210.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 1252210.0 |
|
|  
| | |  |  | |
| |